Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,224 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A multi-institutional validation of the prognostic value of the neutrophil-to-lymphocyte ratio for upper tract urothelial carcinoma treated with radical nephroureterectomy.
Tanaka N, Kikuchi E, Kanao K, Matsumoto K, Shirotake S, Miyazaki Y, Kobayashi H, Kaneko G, Hagiwara M, Ide H, Obata J, Hoshino K, Hayakawa N, Kosaka T, Hara S, Oyama M, Momma T, Nakajima Y, Jinzaki M, Oya M. Tanaka N, et al. Among authors: hara s. Ann Surg Oncol. 2014 Nov;21(12):4041-8. doi: 10.1245/s10434-014-3830-3. Epub 2014 Jun 10. Ann Surg Oncol. 2014. PMID: 24912614
Optimal timing of hormonal therapy for prostate-specific antigen recurrence after radical prostatectomy.
Matsumoto K, Mizuno R, Tanaka N, Ide H, Hasegawa M, Ishida M, Hayakawa N, Yasumizu Y, Hagiwara M, Hara S, Kikuchi E, Miyajima A, Nakagawa K, Nakajima Y, Nakamura S, Nakashima J, Oya M. Matsumoto K, et al. Among authors: hara s. Med Oncol. 2014 Jul;31(7):45. doi: 10.1007/s12032-014-0045-1. Epub 2014 Jun 10. Med Oncol. 2014. PMID: 24913809 Clinical Trial.
Impact of an adjuvant chemotherapeutic regimen on the clinical outcome in high risk patients with upper tract urothelial carcinoma: a Japanese multi-institution experience.
Shirotake S, Kikuchi E, Tanaka N, Matsumoto K, Miyazaki Y, Kobayashi H, Ide H, Obata J, Hoshino K, Kaneko G, Hagiwara M, Kosaka T, Kanao K, Kodaira K, Hara S, Oyama M, Momma T, Miyajima A, Nakagawa K, Hasegawa S, Nakajima Y, Oya M. Shirotake S, et al. Among authors: hara s. J Urol. 2015 Apr;193(4):1122-8. doi: 10.1016/j.juro.2014.10.022. Epub 2014 Oct 13. J Urol. 2015. PMID: 25444957
Impact of Combined Use of Blood-based Inflammatory Markers on Patients with Upper Tract Urothelial Carcinoma Following Radical Nephroureterectomy: Proposal of a Cumulative Marker Score as a Novel Predictive Tool for Prognosis.
Tanaka N, Kikuchi E, Kanao K, Matsumoto K, Shirotake S, Miyazaki Y, Kobayashi H, Kaneko G, Hagiwara M, Ide H, Obata J, Hoshino K, Hayakawa N, Kosaka T, Hara S, Nakagawa K, Jinzaki M, Oya M. Tanaka N, et al. Among authors: hara s. Eur Urol Focus. 2015 Aug;1(1):54-63. doi: 10.1016/j.euf.2015.02.001. Epub 2015 May 23. Eur Urol Focus. 2015. PMID: 28723357 Free article.
History of Non-Muscle-Invasive Bladder Cancer May Have a Worse Prognostic Impact in cT2-4aN0M0 Bladder Cancer Patients Treated With Radical Cystectomy.
Kayama E, Kikuchi E, Fukumoto K, Shirotake S, Miyazaki Y, Hakozaki K, Kaneko G, Yoshimine S, Tanaka N, Takahiro M, Kanai K, Oyama M, Nakajima Y, Hara S, Monma T, Oya M. Kayama E, et al. Among authors: hara s. Clin Genitourin Cancer. 2018 Oct;16(5):e969-e976. doi: 10.1016/j.clgc.2018.04.004. Epub 2018 Apr 28. Clin Genitourin Cancer. 2018. PMID: 29778322
The pretreatment neutrophil-to-lymphocyte ratio is a novel biomarker for predicting clinical responses to pembrolizumab in platinum-resistant metastatic urothelial carcinoma patients.
Ogihara K, Kikuchi E, Shigeta K, Okabe T, Hattori S, Yamashita R, Yoshimine S, Shirotake S, Nakazawa R, Matsumoto K, Mizuno R, Hara S, Oyama M, Masuda T, Niwakawa M, Oya M. Ogihara K, et al. Among authors: hara s. Urol Oncol. 2020 Jun;38(6):602.e1-602.e10. doi: 10.1016/j.urolonc.2020.02.005. Epub 2020 Mar 2. Urol Oncol. 2020. PMID: 32139290
2,224 results